News

Biotechnology

3 Important Things that Happened in the Cannabis Sector This Week

3 Important Things that Happened in the Cannabis Sector This Week

Stephen L Kanaval | Equities.com |

ACB, GWPH and Organigram Holdings makes the list.


Clovis Oncology Gets FDA Priority Review To Expand Label for Cancer Drug

Edward Kim | Equities.com |

Company seeks to expand the use of Rubraca to patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.


Lilly To Acquire Dermira for $1.1 Billion

Edward Kim | Equities.com |

All cash deal will add Phase 3 asset for the treatment of moderate-to-severe atopic dermatitis.


Merck's Keytruda Gets FDA Approval for High-Risk Bladder Cancer

Edward Kim | Equities.com |

Merck's blockbuster drug wins another indication in the ongoing cancer battle.


Veracyte Partners with AstraZeneca Unit to Provide Genomic Data to Develop Oncology Therapeutics

Edward Kim | Equities.com |

Multi-year deal with Acerta Pharma, AstraZeneca's hematology research and development arm.


Arcutis Biotherapeutics Files $100 Million IPO for Dermatological Pipeline

Edward Kim | Equities.com |

The company is pursuing dermatological therapies, with its lead product candidate in Phase 3 clinical trials for plaque psoriasis.


EMD Serono and Pfizer Announce Prolonged Survival With Urothelial Carcinoma Therapy

Edward Kim | Equities.com |

BAVENCIO is the first immunotherapy to significantly prolong overall survival in locally advanced or metastatic urothelial carcinoma in the first-line setting in a Phase III trial.


Illumina and Pacific Biosciences Terminate Merger After FTC Challenge

Edward Kim | Equities.com |

The transaction would have valued PacBio at $1.2 billion.


Intrexon: New CEO, New Name and New Focus To Start the New Year

Edward Kim | Equities.com |

Helen Sabzevari, PhD, named as new President and CEO. Company's new name to be Precigen.


Daiichi Sankyo and AstraZeneca Show Rare Promise Against Advanced Breast Cancer

AP News | Equities.com |

The antibody-drug conjugate staved off cancer for a median of 16 months and shrank tumors in 61% of patients with HER2+ breast cancer.


Humanity. 2.0 - Opening Address at the Vatican

The opening address was delivered by Rev. Philip Larrey, Chairman of. Humanity 2.0, and Matthew. Sanders, CEO & Founder of Humanity 2.0.


Events

Sohn Investment Conference

Wall Street’s best and brightest investors participate in this unique, “must attend” event to share their expertise with an audience of more than 3,000 people, comprised of portfolio managers, asset…

Learn more